



CLINICAL DRUG TESTING

Medication-assisted Treatment

Supporting the complete care of patients with opioid use disorder



We know that caring for patients with opioid use disorder (OUD) takes more than urine drug testing. With clinical and toxicology testing, Labcorp can support you as you help your patients recover and thrive.

Medication-assisted Treatment (MAT)

Our Medication-assisted treatment (MAT) panels were designed specifically for monitoring patients on buprenorphine treatment for OUD. Our MAT drug testing portfolio includes three primary panels, individual drug class options, and personal customization.

Features of all MAT drug test options:

- Buprenorphine results listed at top of report
- Detection thresholds optimized for patients in MAT
- Samples retained for at least four weeks to allow for additional testing
- Buprenorphine, norbuprenorphine, and THC definitive results normalized for creatinine concentration, allowing direct comparison over time
- Detection of naloxone in definitive tests for buprenorphine

Monitoring the norbuprenorphine to buprenorphine ratio over time can help confirm that the patient is taking the medication consistently as prescribed and rule out urine spiking.

Test	Methodology	Potential Utilization
MAT Screen Only	Presumptive testing on all drug classes	Efficient screen option with faster results that may be useful upon intake or if definitive testing is not immediately needed
MAT 1 Monitoring	Presumptive testing on all drug classes, with reflex to definitive testing only on buprenorphine	Useful in established patients where the confirmation of norbuprenorphine metabolite and/or naloxone detection is needed, but other definitive testing may not be required
MAT 2 Monitoring	Presumptive with reflex to definitive on all drug classes	Useful in higher risk patients or where definitive testing would be needed to make clinical decisions



	Buprenorphine Medication Assisted Treatment Screen Only, Urine	Buprenorphine Medication Assisted Treatment Monitoring 1, Urine	Buprenorphine Medication Assisted Treatment Monitoring 2, Urine
Drug/Drug Classes Included	Test No. 739395	Test No. 739394	Test No. 701985
Alcohol Biomarkers (EtG, EtS)	•	•	•
Amphetamines/Methamphetamine	•	•	•
Barbiturates	•	•	•
Benzodiazepines	•	•	•
Buprenorphine	•	•	•
Cannabinoids (THC)	•	•	•
Cocaine	•	•	•
Fentanyl	•	•	•
Methodone	•	•	•
Naloxone		if buprenorphine positive	if buprenorphine positive
Opiates	•	•	•
Heroin Metabolite (6-AM)	•	•	•
Oxycodone/Oxymorphone	•	•	•
Phencyclidine (PCP)	•	•	•
Propoxyphene	•	•	•
Tapentadol	•	•	•
Tramadol	•	•	•
Carisoprodol			•
Gabapentin			•

Urine drug testing is a critical component in patient care for monitoring treatment compliance and may help achieve optimal outcomes when used in conjunction with patient risk assessment. Laboratory testing that is not considered medically necessary may result in coverage denials.

GENERAL HEALTH TESTING

Clinical laboratory testing plays an important role in the overall evaluation of patients suffering from OUD. Behaviors associated with opioid misuse increase the prevalence of infectious diseases, and patients with OUD often have other comorbidities which can complicate treatment. Labcorp's comprehensive clinical test menu can provide the answers you need to help guide holistic treatment of your patients.

Guideline Recommended Baseline Tests for OUD Treatment^{1,2}

Test Name	Test No.
Electrolyte Panel	303754
Metabolic Panel (8), Basic	322758
Complete Blood Count (CBC) With Differential	005009
Hepatic Function Panel (7)	322755
γ-Glutamyl Transferase (GGT)	001958
Prothrombin Time (PT)	005199
Lipid Panel	303756
Urinalysis, Complete With Microscopic Examination	003772
Pregnancy Test, Urine	004036
Hepatitis C Virus (HCV) Antibody With Reflex to Qualitative NAA	144045
Viral Hepatitis Screening and Diagnosis (HAV and HBV)	144552
HIV Antigen/Antibody Combo With Reflex to Confirmation	083935
QuantiFERON® – TB Gold Plus	182879

References

1. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
2. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update [published correction appears in *J Addict Med.* 2020 May/June;14(3):267]. *J Addict Med.* 2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633.

Additional Tests Per Patient History^{1,2}

Test Name	Test No.
RPR with Reflex, completion of reverse cascade for specimens known positive for T. pallidum treponemal antibodies	006026
Chlamydia / Gonococcus, NAA With Reflex to Trichomonas vaginalis, NAA	183198

In addition to the commonly used illicit and prescription drugs in our MAT panels, we also offer an expanded menu of testing for designer and synthetic drugs. Our scientific team works hard to offer you the most relevant testing based on current trends in drug misuse. Additionally, our toxicologists are available to discuss patients results and test options.



Direct access to toxicologists: **866-593-0157**